N. Paul Ohori, MD
Professor of Pathology
Dr. Ohori is Medical Director of Cytopathology, UPMC Presbyterian.
Department of Pathology
200 Lothrop Street
Pittsburgh, PA 15213
Office Telephone: 412-647-9843
- BA - Johns Hopkins University, 1983
- MD - Medical College of Virginia, 1987
Clinical ExpertiseDr. Ohori is a Professor of Pathology in the Division of Anatomic Pathology and Medical Director of Cytopathology at UPMC Presbyterian. He has been a faculty member in the School of Medicine since 1992 and has been involved in medical student, cytotechnology student, resident, and fellow training. He has been the chair of the curriculum committee of the residency program in the Department of Pathology, Board Member of the School of Cytotechnology, and the cytopathology representative to the Molecular Anatomic Pathology Division. From 2001 to 2008, he served as the Director for the Cytopathology Fellowship Program.
Dr. Ohori has provided service to the UPMC system since 1992 and over the last 15 years, he has served as the Medical Director of Cytopathology at UPMC Presbyterian Hospital. His service responsibilities have focused on Non-Gynecologic Cytopathology and Thoracic Surgical Pathology. In this regard, he provides consultative expertise in thyroid, head and neck, pulmonary, and gastrointestinal cytopathology. Dr. Ohori participates in a number of regional and national conferences in the areas of thyroid cytopathology and thoracic pathology.
Research ExpertiseDr. Ohori has focused his efforts in clinically related research in Non-gynecologic Cytopathology. In general, his research involves three main areas: 1. bridging the gap between cytopathology and surgical pathology by emphasizing correlation and understanding of organ specific concepts 2. applying ancillary technologies to refine diagnostic and pathogenetic information, and 3. quality improvement in cytopathology laboratory performance. Specifically, he has investigated the cytologic and molecular manifestations of thyroid, pancreaticobiliary and pulmonary neoplasms. Furthermore, he has been involved in improving cytopathology laboratory performance by developing a systematic method for cytologic-histologic correlation in non-gynecologic cytopathology.
SpecialtiesNon-gynecologic Cytopathology and Pulmonary Pathology
Selected PublicationsView Dr. Ohori's publications on PubMed
Chiosea S, Nikiforova M, Zuo H, Ogilvie J, Gandhi M, Seethala RR, Ohori NP, Nikiforov Y. A novel complex BRAF mutation detected in a solid variant of papillary thyroid carcinoma. Endocr Pathol. 20:122-6, 2009.
Dacic S, Shuai Y, Yousem S, Ohori P, Nikiforova M. Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Mod Pathol 23:159-168, 2010.
Ohori NP, Nikiforova MN, Schoedel KE, LeBeau SO, Hodak SP, Seethala RR, Carty SE, Ogilvie JB, Yip L, Nikiforov YE. Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance". Cancer (Cancer Cytopathol) 118:17-23, 2010.
Seethala S, Jain S, Ohori NP, Monaco S, Lacomis J, Crock F, Nemec J. Focal monomorphic ventricular tachycardia as the first manifestation of amyloid cardiomyopathy. Indian Pacing Electrophysiol J. 10:143-7, 2010.
Fasanella KE, Krasinskas A, Schoedel KE, Sasatomi E, Slivka A, Whitcomb DC, Sanders M, Nodit L, Raab S, McGrath KM, Ohori NP, Khalid A. DNA Mutational Differences in Cytological Specimens from Pancreatic Cancer and Cholangiocarcinoma. Pancreatology. 10:429-433, 2010.
Craig FE, Ohori NP, Gorrill TS, Swerdlow SH. Flow cytometric immunophenotyping of cerebrospinal fluid specimens. Am J Clin Pathol. 135:22-34, 2011.
Tochigi N, Dacic S, Ohori NP. Bronchoscopic and transthoracic cytology and biopsy for pulmonary nonsmall cell carcinomas: performance characteristics by procedure and tumor type. Diagn Cytopathol. 2011 Feb 13. doi: 10.1002/dc.21588. [Epub ahead of print]
Ocque R, Tochigi N, Ohori NP, Dacic S. Utility of immunohistochemistry and histochemistry in the classification of lung adenocarcinoma and squamous cell carcinoma in cytology specimens. Am J Clin Pathol. 136:81-7, 2011.
Marks-Jones DA, Sutkowski BA, Schoedel KE, Ohori NP. Selective screening for nongynecologic cytology specimens: Modifying the screening process for improved efficiency and practice. Diagn Cytopathol. 39:717-22, 2011.
Nikiforov YE, Ohori NP, Hodak SP, Carty SE, Lebeau SO, Ferris RL, Yip L, Seethala RR, Tublin ME, Stang MT, Coyne C, Johnson JT, Stewart AF, Nikiforova MN. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 96:3390-7, 2011.
Khalid A, Dewitt J, Ohori NP, Chen J-H, Fasanella KE, Sanders M, McGrath KM, Nikiforova M. EUS-FNA Mutational Analysis in Differentiating Autoimmune Pancreatitis and Pancreatic Cancer. Pancreatology. 11:482-486, 2011.
Ohori NP, Schoedel KE. Variability in the atypia of undetermined significance/follicular lesion of undetermined significance diagnosis in the bethesda system for reporting thyroid cytopathology: sources and recommendations. Acta Cytol. 55:492-8, 2011.